Gilead Sciences (GILD) : Pillar Pacific Capital Management scooped up 1,268 additional shares in Gilead Sciences during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 3, 2016. The investment management firm now holds a total of 97,410 shares of Gilead Sciences which is valued at $8,248,679.Gilead Sciences makes up approximately 1.43% of Pillar Pacific Capital Management’s portfolio.
Other Hedge Funds, Including , Harfst Associates sold out all of its stake in GILD during the most recent quarter. The investment firm sold 58 shares of GILD which is valued $4,911.Evanston Investments Dba Evanston Advisors boosted its stake in GILD in the latest quarter, The investment management firm added 3,230 additional shares and now holds a total of 64,101 shares of Gilead Sciences which is valued at $5,428,073. Gilead Sciences makes up approx 1.84% of Evanston Investments Dba Evanston Advisors’s portfolio.Nordea Investment Management Ab boosted its stake in GILD in the latest quarter, The investment management firm added 413,849 additional shares and now holds a total of 2,420,311 shares of Gilead Sciences which is valued at $213,495,633. Gilead Sciences makes up approx 0.64% of Nordea Investment Management Ab’s portfolio.Eads Heald Investment Counsel reduced its stake in GILD by selling 110 shares or 1.45% in the most recent quarter. The Hedge Fund company now holds 7,497 shares of GILD which is valued at $661,310. Gilead Sciences makes up approx 0.46% of Eads Heald Investment Counsel’s portfolio.Morgens Waterfall Vintiadis Co Inc reduced its stake in GILD by selling 22,800 shares or 34.13% in the most recent quarter. The Hedge Fund company now holds 44,000 shares of GILD which is valued at $3,881,240. Gilead Sciences makes up approx 3.63% of Morgens Waterfall Vintiadis Co Inc’s portfolio.
Gilead Sciences opened for trading at $86.41 and hit $86.48 on the upside on Tuesday, eventually ending the session at $86.18, with a gain of 0.60% or 0.51 points. The heightened volatility saw the trading volume jump to 68,40,044 shares. Company has a market cap of $114,776 M.
On the company’s financial health, Gilead Sciences reported $3.03 EPS for the quarter, missing the analyst consensus estimate by $ -0.10 based on the information available during the earnings call on Apr 28, 2016. Analyst had a consensus of $3.13. The company had revenue of $7794.00 million for the quarter, compared to analysts expectations of $8065.42 million. The company’s revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.94 EPS.
Many Wall Street Analysts have commented on Gilead Sciences. Gilead Sciences was Downgraded by Maxim Group to ” Hold” on Apr 29, 2016. Shares were Reiterated by UBS on Apr 29, 2016 to “Buy” and Lowered the Price Target to $ 118 from a previous price target of $130 .Shares were Reiterated by Leerink Partners on Mar 16, 2016 to “Outperform” and Lowered the Price Target to $ 127 from a previous price target of $130 .
Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.